Drug Trial Radar · NCT07727538
A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jul 31, 2026
Primary completion
Aug 2030
Study completion Aug 2031
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Jul 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the efficacy of olezarsen administered by subcutaneous injection to pediatric participants with FCS.
Conditions
- Familial Chylomicronemia Syndrome
Interventions
OlezarsenDrug
Olezarsen will be administered by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Fasting Triglycerides (TG)Time frame: At 6 Months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama · Recruiting
UCSF Benioff Children's Hospital
San Francisco, California · Recruiting
Children's Mercy Hospital
Kansas City, Missouri · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
Cook Children's Medical Center
Fort Worth, Texas · Recruiting
Mary Bridge Children's
Tacoma, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.